BridgeBio Pharma, Inc. (BBIO) News
Filter BBIO News Items
BBIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BBIO News Highlights
- BBIO's 30 day story count now stands at 7.
- Over the past 23 days, the trend for BBIO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about BBIO are ACM, ALTO and BASE.
Latest BBIO News From Around the Web
Below are the latest news stories about BRIDGEBIO PHARMA INC that investors may wish to consider to help them evaluate BBIO as an investment opportunity.
With BridgeBio Pharma's DNA, the Stock Could Continue to Soar HigherBridgeBio Pharma has made a base pattern. The company finds, develops, and delivers breakthrough medicines for genetic diseases - a worthy mission. In this daily bar chart of BBIO, below, I can see that prices have climbed four-fold in the past twelve months. |
13 High Growth Healthcare Stocks to BuyIn this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this article, we have defined high growth stocks as stocks that […] |
3 Russell 2000 Stocks That Are About to Get Absolutely CrushedThe Russell 2000 has only begun closing its wide gap with other indices, but investors should be weary of these three stocks to sell. |
BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia- BridgeBio has dosed the first child in PROPEL 3, a one-year, 2:1 randomized, placebo-controlled Phase 3 pivotal trial evaluating the efficacy and safety of infigratinib in children with achondroplasia - The U.S. Food and Drug Administration (FDA) and European Union (EU) European Medicines Agency (EMA) shared positive feedback that the PROPEL 3 trial design would be acceptable as a registrational study to support a marketing application - Data from PROPEL 2, BridgeBio’s Phase 2 clinical trial o |
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PALO ALTO, Calif., Dec. 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on December 05, 2023, the compensation committee of BridgeBio’s board of directors granted thirty new employees restricted stock units for an aggregate of 147,373 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock |
12 Most Promising Stocks to Buy According to Hedge FundsIn this article, we will take a look at the 12 most promising stocks to buy according to hedge funds. To see more such companies, go directly to 5 Most Promising Stocks to Buy According to Hedge Funds. Analysts and financial institutions are starting to release their 2024 market outlook reports and predictions and you […] |
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)- NDA submission is based on positive results from ATTRibute-CM Phase 3 study, including a highly statistically significant result, demonstrated by a Win Ratio of 1.8 (p<0.0001), on the primary endpoint (a hierarchical analysis prioritizing in order all-cause mortality (ACM), then frequency of cardiovascular-related hospitalization (CVH), then change from baseline in N-terminal prohormone of brain natriuretic peptide (NT-proBNP), then change from baseline in 6-minute walk distance (6MWD)) - In A |
Insider Sell Alert: BridgeBio Pharma Inc's Brian Stephenson Unloads 22,685 SharesIn a notable insider transaction, Brian Stephenson, the Secretary, Treasurer & CFO of BridgeBio Pharma Inc (NASDAQ:BBIO), sold 22,685 shares of the company on November 17, 2023. |
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related hospitalization) was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001) - The placebo and acoramidis time-to-first event Kaplan-Meier (K-M) curves for a composite of all-cause mortality (ACM) and cardiovascular-related hospitalization (CVH) separated beginning at Month 3, representing the most rapid & sustained clinical b |
BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023PALO ALTO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that additional Phase 3 data on clinical outcomes from ATTRibute-CM, its study of acoramidis in ATTR-CM will be presented at the AHA Scientific Sessions 2023, taking place in Philadelphia, Pennsylvania on November 11 - 13, 2023. As previously announced, a highly statisticall |